Germany· DE-A57-087af4ab0e3bdbb4
Amifampridin Hormosan
A amifampridine product containing amifampridine phosphate, registered in Germany by Hormosan Pharma Gmbh. The same ATC class is registered in 16 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Amifampridine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 9 of them publish a price we can compare per daily dose
Amifampridine · ATC N07XX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amifampridine costs, country by country.
Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amifampridine · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- FR France$3657.38
- CH Switzerland$75.59
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Amifampridine Phosphate
- Manufacturer
- Hormosan Pharma Gmbh
- Country
- Germany (DE)
- ATC code
- N07XX05
- ATC class
- Amifampridine
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for amifampridine.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amifampridine · interactions on record
82 records
- 4 severe
- 78 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amifampridine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United Kingdom3,4-Diaminopyridine 10mg tabletsSpecial Order
- NetherlandsAmifampridine Accord 10 mg tablettenAccord Healthcare B.V.
- CzechiaAMIFAMPRIDINE SERBSERB S.A., Brusel
- NorwayAmifampridine AccordAccord Healthcare B.V.
- PolandAmifampridine Medical ValleyMedical Valley Invest AB
- FranceAMIFAMPRIDINE SERB 10 mg, compriméSERB (BELGIQUE)
- BelgiumAmifampridine Serb 10 mgSERB
- CanadaFIRDAPSEKYE PHARMACEUTICALS INC.
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- France · Amifampridine Amarox, Amifampridine Biogaran
- Hungary · Amifampridine Accord
- Iceland · Amifampridine Serb, Firdapse
- Italy · Amifampridina Accord
- Liechtenstein · Amifampridine Serb, Firdapse
- Netherlands · Amifampridine Accord, Amifampridine Amarox
- Norway · Amifampridin Medical Valley, Amifampridine Accord
- Poland · Amifampridine Medical Valley
- Portugal · Amifampridina Accord, Amifampridina Generis
- Slovenia · Amifampridin Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec578e6c-76d2-444c-b8f8-1ae5523e6fad GET /v1/drugs/ec578e6c-76d2-444c-b8f8-1ae5523e6fad?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Amifampridine Phosphate",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about amifampridine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.